Boston Millennia Partners Intends to Vote Against Proposed Merger of SomaLogic With Standard BioTools

12/31/23 2:10:00 PM ET

$LAB

$SLGC

Biotechnology: Laboratory Analytical Instruments

Industrials

Biotechnology: Commercial Physical & Biological Resarch

Health Care

Get the next $LAB alert in real time by email

Boston Millennia Partners ("Boston Millennia"), a significant shareholder of SomaLogic (the "Company") (NASDAQ:SLGC) today announced that it intends to vote against the Company's planned merger (the "Merger") with Standard BioTools Inc. (NASDAQ:LAB).

View source version on businesswire.com: https://www.businesswire.com/news/home/20231231077712/en/

Get the next $LAB alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$LAB
$SLGC

Company	Date	Price Target	Rating	Analyst
Standard BioTools Inc. $LAB	4/16/2024	$3.50	Buy	TD Cowen
Standard BioTools Inc. $LAB	4/4/2024	$3.25	Buy	Jefferies
SomaLogic Inc. $SLGC	10/5/2023	$3.50 → $2.29	Buy → Hold	Jefferies
SomaLogic Inc. $SLGC	9/25/2023	$5.00 → $2.50	Buy → Hold	Canaccord Genuity
Standard BioTools Inc. $LAB	7/12/2023	$4.00	Overweight	KeyBanc Capital Markets
SomaLogic Inc. $SLGC	2/1/2022	$12.00	Buy	Stifel
SomaLogic Inc. $SLGC	12/14/2021	$19.00	Buy	Canaccord Genuity
SomaLogic Inc. $SLGC	12/10/2021	$16.00	Buy	Jefferies

More analyst ratings

$LAB
$SLGC
Financials

Live finance-specific insights

Standard BioTools Reports Third Quarter 2024 Financial Results
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) (the "Company") today announced unaudited interim financial results for the third quarter ended September 30, 2024. Recent Highlights: Reported third quarter 2024 revenue of $45 million Ongoing merger cost synergy realization delivered 50% adjusted EBITDA improvement and 35% net loss improvement year-over-yearOperationalized approximately $80 million in merger synergies, expected to be fully realized in 2025, and reinforcing path to adjusted EBITDA break-even in 2026Balance sheet as of September 30, 2024, includes $368 million cash, cash equivalents, restricted cash and short-te
10/30/24 4:01:00 PM ET
$LAB
Biotechnology: Laboratory Analytical Instruments
Industrials
Standard BioTools Announces Conference Call and Webcast for Third Quarter 2024 Financial Results on October 30, 2024
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) today announced that it will report third quarter 2024 financial results on Wednesday, October 30, 2024, after the close of the market. The Company's management will host a conference call and webcast at 1:30 p.m. PT, 4:30 p.m. ET, on October 30, 2024, to discuss third quarter 2024 financial results and operational progress. A press release including the financial results will be publicly distributed before the call. Individuals interested in listening to the conference call may do so by dialing: US domestic callers: (888) 346-3970Outside US callers: (412) 902-4297 Live audio of the webca
10/16/24 8:00:00 AM ET
$LAB
Biotechnology: Laboratory Analytical Instruments
Industrials
Standard BioTools Reports Second Quarter 2024 Financial Results
Delivered revenue of $37.2 million Accelerated merger synergies with $80 million expected to be operationalized in 2024 Revised FY2024 revenue guidance; on-track to achieve anticipated break-even adjusted EBITDA for full-year 2026 Current balance sheet of $396 million cash, cash equivalents, restricted cash and short-term investments SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. ("Standard BioTools" or the "Company") (NASDAQ:LAB) today announced unaudited interim financial results for the second quarter and six months ended June 30, 2024. "We are laser-focused on optimizing our cost structure, already seeing early integration synerg
7/31/24 4:01:00 PM ET
$LAB
Biotechnology: Laboratory Analytical Instruments
Industrials

Standard BioTools Appoints Alex Kim as Chief Financial Officer
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. ("Standard BioTools" or the "Company") (NASDAQ:LAB) today announced the appointment of Alex Kim as Chief Financial Officer, effective November 11, 2024. Kim, a co-founder and most recently Chief Operating Officer of Standard BioTools, brings nearly 30 years of financial and operations experience in the healthcare and life sciences industries to the role and will oversee Standard BioTools' finance organization. Michael Egholm, President and Chief Executive Officer of Standard BioTools, said, "I am thrilled to announce Alex as our next CFO. Having co-founded Standard BioTools with me, Alex's deep understan
11/7/24 8:00:00 AM ET
$LAB
Biotechnology: Laboratory Analytical Instruments
Industrials
Standard BioTools to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) today announced that its management team will participate in the following investor conferences in the month of November: UBS Global Healthcare Conference on November 12th, 2024President and CEO, Michael Egholm, PhD, will participate in a corporate presentation on Tuesday, November 12, 2024, at 1:15 p.m. PTJefferies London Healthcare Conference on November 19th – 21st, 2024President and CEO, Michael Egholm, PhD, will participate in a corporate presentation on Tuesday, November 19, 2024, at 8:30 a.m. GMT Available presentations will be webcast live and available on the Investor Relat
10/31/24 8:01:00 AM ET
$LAB
Biotechnology: Laboratory Analytical Instruments
Industrials
Standard BioTools Reports Third Quarter 2024 Financial Results
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) (the "Company") today announced unaudited interim financial results for the third quarter ended September 30, 2024. Recent Highlights: Reported third quarter 2024 revenue of $45 million Ongoing merger cost synergy realization delivered 50% adjusted EBITDA improvement and 35% net loss improvement year-over-yearOperationalized approximately $80 million in merger synergies, expected to be fully realized in 2025, and reinforcing path to adjusted EBITDA break-even in 2026Balance sheet as of September 30, 2024, includes $368 million cash, cash equivalents, restricted cash and short-te
10/30/24 4:01:00 PM ET
$LAB
Biotechnology: Laboratory Analytical Instruments
Industrials

$LAB
$SLGC
Leadership Updates

Live Leadership Updates

Standard BioTools Appoints Alex Kim as Chief Financial Officer
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. ("Standard BioTools" or the "Company") (NASDAQ:LAB) today announced the appointment of Alex Kim as Chief Financial Officer, effective November 11, 2024. Kim, a co-founder and most recently Chief Operating Officer of Standard BioTools, brings nearly 30 years of financial and operations experience in the healthcare and life sciences industries to the role and will oversee Standard BioTools' finance organization. Michael Egholm, President and Chief Executive Officer of Standard BioTools, said, "I am thrilled to announce Alex as our next CFO. Having co-founded Standard BioTools with me, Alex's deep understan
11/7/24 8:00:00 AM ET
$LAB
Biotechnology: Laboratory Analytical Instruments
Industrials
Madryn Asset Management, a Top Shareholder of SomaLogic, Issues Letter Regarding Opposition to the Company's Proposed Merger with Standard BioTools
Files Preliminary Proxy Statement to Solicit Shareholders to Oppose the Merger Intends to Vote AGAINST the Conflict-Plagued and Excessively Dilutive Transaction, Which Stands to Unduly Benefit Certain Investors and Standard BioTools at the Expense of SomaLogic's Shareholders Notes the Current Premium for SomaLogic Shareholders, Based on the Deal's Exchange Ratio and Standard BioTools' Trading Price, is Only ~4.3% Underscores That SomaLogic Has Superior Alternatives to a Flawed Combination, Including a Standalone Path Leveraging its Considerable Cash Position and Strong Balance Sheet Madryn Asset Management, LP (collectively with its affiliates, "Madryn"), a holder of approximately 4
12/12/23 5:31:00 PM ET
$EXAS
$ILMN
$LAB
$ME
Medical Specialities
Health Care
Biotechnology: Laboratory Analytical Instruments
Industrials
SomaLogic Announces Chief Financial Officer Transition
Appoints Eliot M. Lurier, CPA, as Interim Chief Financial Officer Reaffirms 2023 Financial Guidance BOULDER, Colo., June 06, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc. (NASDAQ:SLGC), a leader in proteomics technology, today announced a Chief Financial Officer transition. Eliot M. Lurier, CPA, is joining the company as Interim CFO while the Company conducts a search for a permanent CFO. Shaun Blakeman has left the company, effective June 5, 2023. Mr. Lurier has over 35 years of experience in financial and leadership positions across the life science industry. He will report directly to the Interim CEO and immediately embed within the finance organization to ensure a seamless transiti
6/6/23 4:05:00 PM ET
$SLGC
Biotechnology: Commercial Physical & Biological Resarch
Health Care

Boston Millennia Partners Intends to Vote Against Proposed Merger of SomaLogic With Standard BioTools

Chat with this insight

Recent Analyst Ratings for $LAB$SLGC

$LAB$SLGC SEC Filings

Standard BioTools Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

SEC Form 10-Q filed by Standard BioTools Inc.

Standard BioTools Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

$LAB$SLGC Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Casdin Partners Master Fund, L.P. bought $546,750 worth of shares (250,000 units at $2.19) (SEC Form 4)

Director Casdin Partners Master Fund, L.P. bought $1,546,237 worth of shares (750,000 units at $2.06) (SEC Form 4)

Director Casdin Partners Master Fund, L.P. bought $2,351,875 worth of shares (1,250,000 units at $1.88) (SEC Form 4)

$LAB$SLGC Financials

Live finance-specific insights

Standard BioTools Reports Third Quarter 2024 Financial Results

Standard BioTools Announces Conference Call and Webcast for Third Quarter 2024 Financial Results on October 30, 2024

Standard BioTools Reports Second Quarter 2024 Financial Results

$LAB$SLGC Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

TD Cowen initiated coverage on Standard BioTools with a new price target

Jefferies initiated coverage on Standard BioTools with a new price target

SomaLogic downgraded by Jefferies with a new price target

$LAB$SLGC Press Releases

Fastest customizable press release news feed in the world

$LAB$SLGC Market Insights

Live Market Insights

$LAB$SLGC Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Standard BioTools Appoints Alex Kim as Chief Financial Officer

Standard BioTools to Participate in Upcoming Investor Conferences

Standard BioTools Reports Third Quarter 2024 Financial Results

Standard Biotools Filed For Offering Of Up To 105.1M Common Shares By The Selling Securityholders

Standard BioTools Purchases The Carterra LSA-XT System; No Financial Terms Disclosed

$1.5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying

President & CEO Egholm Michael covered exercise/tax liability with 28,795 shares, decreasing direct ownership by 2% to 1,473,704 units (SEC Form 4)

SVP & Chief Financial Officer Black Jeffrey G. covered exercise/tax liability with 6,690 shares, decreasing direct ownership by 2% to 421,608 units (SEC Form 4)

President & CEO Egholm Michael covered exercise/tax liability with 29,093 shares, decreasing direct ownership by 2% to 1,502,499 units (SEC Form 4)

$LAB$SLGC Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Standard BioTools Inc.

Amendment: SEC Form SC 13G/A filed by Standard BioTools Inc.

Amendment: SEC Form SC 13G/A filed by Standard BioTools Inc.

$LAB$SLGC Leadership Updates

Live Leadership Updates

Standard BioTools Appoints Alex Kim as Chief Financial Officer

Madryn Asset Management, a Top Shareholder of SomaLogic, Issues Letter Regarding Opposition to the Company's Proposed Merger with Standard BioTools

SomaLogic Announces Chief Financial Officer Transition

Recent Analyst Ratings for
$LAB
$SLGC

$LAB
$SLGC
SEC Filings

$LAB
$SLGC
Insider Purchases

$LAB
$SLGC
Financials

$LAB
$SLGC
Analyst Ratings

$LAB
$SLGC
Press Releases

$LAB
$SLGC
Market Insights

$LAB
$SLGC
Insider Trading

$LAB
$SLGC
Large Ownership Changes

$LAB
$SLGC
Leadership Updates